Skip to content
terazosin

Structure via PubChem · Public domain (PubChem)

EntityQ280786· pop 18· linked from 612 articles

Also known as ABBOTT-45975, Hytrin®, Terazosine, 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)piperazine, Térazosine, Terazosina, Terazosinum

Chemical data

Formula
C19H25N5O4
Molecular weight
387.4 g/mol
IUPAC name
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone
SMILES
COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC
InChIKey
VCKUSRYTPJJLNI-UHFFFAOYSA-N
XLogP
1.4
Polar surface area
103 Ų
H-bond donors
1
H-bond acceptors
8
Formal charge
0

via PubChem

Drug data · ChEMBL

Max clinical phase
Approved
Molecule type
Small molecule
First approval
1987
Admin. routes
oral
Indications
benign prostatic hyperplasia, internal carotid artery stenosis, hypertension, atherosclerosis

via ChEMBL · EBI

Wikidata facts

Mass
387.191
Has use
medication
Show 7 more facts
chemical formula
C₁₉H₂₅N₅O₄
medical condition treated
arterial hypertension
canonical SMILES
COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC
World Health Organisation international non-proprietary name
terazosin
defined daily dose
5
Commons category
Terazosin
significant drug interaction
levobunolol
Sources (8)

via Wikidata · CC0

~2 min read

Encyclopedic overview

3 sections
Contents
  • Synthesis
  • Research on neuroprotective effects
  • References

Terazosin, sold under the brand name Hytrin among others, is a medication used to treat symptoms of an enlarged prostate and high blood pressure. For high blood pressure, it is a less preferred option. It is taken by mouth.

Common side effects include dizziness, headache, feeling tired, swelling, nausea, and low blood pressure with standing. Severe side effects may include priapism and low blood pressure. Prostate cancer should be ruled out before starting treatment. It is an alpha-1 blocker and works by relaxing blood vessels and the opening of the bladder.

Excerpted from Wikipedia’s “terazosin” article, available under the CC BY-SA 4.0 licence.

Gallery (2)